Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy

Next Previous
Trial Profile

An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Expanded access; Therapeutic Use
  • Acronyms CBD

Most Recent Events

  • 04 May 2015 New source identified and integrated (ClinicalTrials.gov record : NCT02397863)
  • 22 Apr 2015 Data from 137 patients in this expanded access program were presented a the American Academy of Neurology Annual Meeting 2015, according to a GW Pharmaceuticals media release.
  • 22 Apr 2015 A GW Pharmaceuticals media release announced physician reports in 137 patients in this expanded access program.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top